248 related articles for article (PubMed ID: 15472795)
1. A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection.
Manfredi R; Nanetti A; Morelli S; Ferri M; Valentini R; Calza L; Chiodo F
HIV Clin Trials; 2004; 5(4):206-15. PubMed ID: 15472795
[TBL] [Abstract][Full Text] [Related]
2. Role of Mycobacterium xenopi disease in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Comparison with the pre-Haart period.
Manfredi R; Nanetti A; Tadolini M; Calza L; Morelli S; Ferri M; Marinacci G
Tuberculosis (Edinb); 2003; 83(5):319-28. PubMed ID: 12972345
[TBL] [Abstract][Full Text] [Related]
3. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Research Committee of the British Thoracic Society
Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
[TBL] [Abstract][Full Text] [Related]
4. In vitro sensitivity of Mycobacterium xenopi to five antibiotics.
Dauendorffer JN; Laurain C; Weber M; Dailloux M
Pathol Biol (Paris); 2002 Dec; 50(10):591-4. PubMed ID: 12504367
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary Mycobacterium xenopi infection in AIDS patients treated with HAART in Hungary.
Szlávik J; Sárvári C
Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):701-3. PubMed ID: 14557921
[TBL] [Abstract][Full Text] [Related]
6. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients.
Foudraine NA; Hovenkamp E; Notermans DW; Meenhorst PL; Klein MR; Lange JM; Miedema F; Reiss P
AIDS; 1999 Feb; 13(2):177-84. PubMed ID: 10202823
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and treatment of atypical mycobacterial infections of the respiratory tract].
Andréjak C; Lescure FX; Schmit JL; Jounieaux V
Rev Mal Respir; 2011 Dec; 28(10):1293-309. PubMed ID: 22152937
[TBL] [Abstract][Full Text] [Related]
8. Mycobacterium xenopi infection in patients with human immunodeficiency virus infection.
el-Helou P; Rachlis A; Fong I; Walmsley S; Phillips A; Salit I; Simor AE
Clin Infect Dis; 1997 Aug; 25(2):206-10. PubMed ID: 9332511
[TBL] [Abstract][Full Text] [Related]
9. Increasing incidence of Mycobacterium xenopi at Bellevue hospital: An emerging pathogen or a product of improved laboratory methods?
Donnabella V; Salazar-Schicchi J; Bonk S; Hanna B; Rom WN
Chest; 2000 Nov; 118(5):1365-70. PubMed ID: 11083687
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment.
Jenkins PA; Campbell IA;
Respir Med; 2003 Apr; 97(4):439-44. PubMed ID: 12693807
[TBL] [Abstract][Full Text] [Related]
11. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
12. Factors which influence treatment initiation for pulmonary non-tuberculous mycobacterium infection in HIV negative patients; a multicentre observational study.
Rawson TM; Abbara A; Kranzer K; Ritchie A; Milburn J; Brown T; Adeboyeku D; Buckley J; Davidson RN; Berry M; Kon OM; John L
Respir Med; 2016 Nov; 120():101-108. PubMed ID: 27817806
[TBL] [Abstract][Full Text] [Related]
13. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London.
Davies BS; Roberts CH; Kaul S; Klein JL; Milburn HJ
Scand J Infect Dis; 2012 Nov; 44(11):815-9. PubMed ID: 23078529
[TBL] [Abstract][Full Text] [Related]
14. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China.
Zhang Z; Pang Y; Wang Y; Cohen C; Zhao Y; Liu C
Int J Antimicrob Agents; 2015 May; 45(5):491-5. PubMed ID: 25795316
[TBL] [Abstract][Full Text] [Related]
15. [Lung diseases due to opportunistic environmental Mycobacteria in patients uninfected with human immunodeficiency virus. Risk factors, clinical and diagnostic aspects and course].
Martínez Moragón E; Menéndez R; Santos M; Lorente R; Marco V
Arch Bronconeumol; 1996 Apr; 32(4):170-5. PubMed ID: 8689013
[TBL] [Abstract][Full Text] [Related]
16. [Changes in the kidneys in patients with successive findings of Mycobacterium xenopi and Mycobacterium fortuitum in the urine--report of 16 cases]].
Lovodić-Sivcev B; Vukelić A
Med Pregl; 1999; 52(9-10):334-42. PubMed ID: 10624381
[TBL] [Abstract][Full Text] [Related]
17. [Atypical mycobacterial infections].
Dautzenberg B; Mercat A
Presse Med; 1994 Oct; 23(32):1483-8. PubMed ID: 7824469
[TBL] [Abstract][Full Text] [Related]
18. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS.
Shafer RW; Sierra MF
Clin Infect Dis; 1992 Jul; 15(1):161-2. PubMed ID: 1617056
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review.
Varadi RG; Marras TK
Int J Tuberc Lung Dis; 2009 Oct; 13(10):1210-8. PubMed ID: 19793424
[TBL] [Abstract][Full Text] [Related]
20. [No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients].
Stephan C; Just-Nübling G; Franck S; Bickel M; Shah PM; Babacan E; Staszewski S
Med Klin (Munich); 2008 Feb; 103(2):69-74. PubMed ID: 18270662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
